TG Therapeutics (NASDAQ:TGTX) Issues Quarterly Earnings Results

Key Points

• TG reported Q1 EPS of $0.12, missing consensus by $0.11, but revenue jumped 69.5% YoY to $204.9M driven by roughly $195M in U.S. BRIUMVI sales, and management raised full‑year U.S. guidance to $885M–$900M (global ~$925M) with Q2 targeting ~$220M.
• Commercial momentum remains strong with >25,000 patients prescribed globally, 12 consecutive quarters of sequential growth and record new patient starts, and topline Phase III ENHANCE data (single 600 mg initiation infusion) is expected in the coming weeks — a positive result could enable a one‑infusion start and potential launch next year.
• Management repurchased ~$100M of stock this quarter (~5% of shares), holds ~$573M in cash after extending financing, expects ~$100M of subcutaneous manufacturing costs this year, and the stock surged ~16% on the results amid analyst price‑target upgrades (consensus ~$52.50).

TG Therapeutics (NASDAQ:TGTX - Get Free Report) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.11), Briefing.com reports. The business had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%.The company's quarterly revenue was up 69.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.03 EPS.

Here are the key takeaways from TG Therapeutics' conference call:

• TG Therapeutics reported approximately $195 million in U.S. BRIUMVI net revenue in Q1 (>$200M globally), beat guidance and raised full‑year U.S. guidance to $885M–$900M (global ~$925M) with Q2 targeting ~$220M.
• Commercial momentum shows durable adoption: >25,000 patients prescribed globally, 12 consecutive quarters of sequential growth, record new patient starts, improving persistence versus prior expectations, and leading dynamic CD20 share in private infusion practices.
• Near‑term pipeline catalyst — top‑line data from the Phase III ENHANCE trial (single 600 mg initiation infusion vs. two‑infusion regimen) is expected in the coming weeks, and a positive result could enable a consolidated one‑infusion start and potential launch next year.
• Subcutaneous BRIUMVI program is fully enrolled in Phase III with topline expected year‑end/early next year (Phase I bioavailability data also due soon); management targets a potential 2028 launch and says sub‑Q could materially expand the addressable anti‑CD20 market.
• Capital allocation and balance sheet: the company repurchased ~$100M of stock this quarter (≈6.8M shares total, ~5% of shares outstanding) and has ~$573M in cash/equivalents after extending the Blue Owl facility, while guiding for ~$100M of subcutaneous manufacturing/secondary manufacturer startup costs to be expensed this year.

TG Therapeutics Trading Up 16.3%

NASDAQ TGTX traded up $5.87 on Wednesday, hitting $41.97. 6,586,922 shares of the stock were exchanged, compared to its average volume of 2,086,136. TG Therapeutics has a 52-week low of $25.28 and a 52-week high of $42.09. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.10 and a quick ratio of 3.29. The company has a market capitalization of $6.43 billion, a price-to-earnings ratio of 15.15 and a beta of 1.68. The company's 50-day moving average price is $32.24 and its two-hundred day moving average price is $31.49.

Hedge Funds Weigh In On TG Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TGTX. Man Group plc grew its position in TG Therapeutics by 621.5% during the 3rd quarter. Man Group plc now owns 1,008,462 shares of the biopharmaceutical company's stock worth $36,431,000 after purchasing an additional 868,697 shares in the last quarter. Goldman Sachs Group Inc. grew its position in TG Therapeutics by 35.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,051,132 shares of the biopharmaceutical company's stock worth $61,144,000 after purchasing an additional 531,759 shares in the last quarter. Invesco Ltd. grew its holdings in shares of TG Therapeutics by 47.1% during the 4th quarter. Invesco Ltd. now owns 1,609,815 shares of the biopharmaceutical company's stock valued at $47,989,000 after acquiring an additional 515,481 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of TG Therapeutics by 1,725.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 472,787 shares of the biopharmaceutical company's stock valued at $14,094,000 after acquiring an additional 446,884 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in shares of TG Therapeutics by 132.4% during the 4th quarter. Millennium Management LLC now owns 675,910 shares of the biopharmaceutical company's stock valued at $20,149,000 after acquiring an additional 385,023 shares in the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on TGTX shares. HC Wainwright lifted their price target on shares of TG Therapeutics from $60.00 to $70.00 and gave the stock a "buy" rating in a research report on Wednesday. Zacks Research lowered shares of TG Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Friday, May 1st. Cantor Fitzgerald restated an "overweight" rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. Weiss Ratings upgraded shares of TG Therapeutics from a "hold (c)" rating to a "hold (c+)" rating in a research report on Friday. Finally, The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $37.00 to $39.00 and gave the stock a "neutral" rating in a research report on Thursday, January 15th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $52.50.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.